PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) — Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use of its TissueCypher Barrett’s Esophagus Assay in determining the risk of progression to esophageal cancer (EC) in patients with Barrett’s esophagus (BE) will be presented during an oral session at Digestive Disease Week (DDW) 2019.
The study was conducted by clinicians at Cleveland Clinic and the University of Pittsburgh School of Medicine, in collaboration with Cernostics. DDW 2019, the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, is taking place in San Diego, May 18 – 21, 2019.
“Independent validation of TissueCypher is an important milestone that provides physicians and patients additional confidence that this innovative approach can improve management of BE and reduce the risk of progression to EC,” said Mike Hoerres, Cernostics’ CEO. “We look forward to the presentation of the results of this study, and believe they add to the growing body of evidence demonstrating that TissueCypher provides independent prognostic information for clinicians that cannot be attained by other methods. The TissueCypher platform uniquely evaluates protein expression of multiple biomarkers in the context of tissue structure of esophageal biopsies, and does so in a highly objective and quantitative manner.”
Independent Validation of a Tissue Systems Pathology Test to Predict Progression in Barrett’s Esophagus Patients
Session Type: Clinical Symposium #1068
Session Title: Challenges and Controversies in Barrett’s Esophagus
Date: May 21, 2019 Time: 2:15 – 2:30 p.m. Location: SDCC Room 33ABC
DDW attendees are invited to attend the oral scientific session being presented by Rebecca Critchley-Thorne, Ph.D., Chief Scientific Officer at Cernostics.
BE affects more than three million Americans, occurring when chronic exposure to stomach acid causes the esophageal cell lining to deteriorate and undergo changes that can create an environment for cancer. Without treatment, Barrett’s can lead to EC, with a poor 5-year survival of less than 20%. Today, Barrett’s is commonly managed by surveillance, involving regular endoscopic procedures with biopsy, monitoring disease progression, and GERD-related drug therapy to control symptoms and prevent esophageal injury.
Cernostics, a leader in tissue-based diagnostic testing, providing diagnostic tests with deeper tissue insights, better patient outcomes and lower cost of care. Cernostics’ mission is to quantify the tissue system complexity, providing physicians and patients with individualized, actionable information to improve outcomes and reduce the incidence and mortality of cancer. For a complete listing of Cernostics’ published patents, visit https://staging.cernostics.com/tissuecypher-technology.